Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | DHODH | Q02127 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | CFTR | P13569 | 2/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.30 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | XPO1 | O14980 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31440810 | 1.00 | HTT (0.33) | HTTDHODHHSP90AA1HSP90AB1HSD11B1 | |
| SCHEMBL30631410 | 0.77 | NQO2 (0.36) | HTTDHODHHSP90AA1HSP90AB1HSD11B1 | |
| SCHEMBL26615963 | 0.77 | NQO2 (0.36) | HTTDHODHHSP90AA1HSP90AB1HSD11B1 | |
| SCHEMBL11278333 | 0.77 | PIK3CD (0.36) | CFTRNT5EMBOAT4HPGDHSD17B10 | |
| SCHEMBL25251476 | 0.74 | NQO2 (0.39) | HTTHPGD | |
| SCHEMBL30309241 | 0.74 | NQO2 (0.39) | HTTHPGD | |
| SCHEMBL30631413 | 0.73 | NQO2 (0.33) | HTTMBOAT4HPGD | |
| SCHEMBL15195547 | 0.73 | NQO2 (0.33) | HTTMBOAT4HPGD | |
| SCHEMBL31018120 | 0.72 | AR (0.35) | HTTHSD11B1ARNOTUMMBOAT4 | |
| SCHEMBL21956967 | 0.72 | AR (0.35) | HTTHSD11B1ARNOTUMMBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4511116-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| WO-2023205463-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205463-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | HTT 348/4885DHODH 946/4885HSP90AA1 868/4885 |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | TRPV1, SCN3A, KCNN3 | HTT 348/4885DHODH 946/4885HSP90AA1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.